Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients

April 20, 2012 updated by: Richard A. Rovin, MD FACS, Marquette General Health System

Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?

Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF) circulating in the blood stream of patients diagnosed with either a meningioma or a glioma. The questions that will be addressed include:

  1. Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?
  2. Is the VEGF level an indicator of the response to treatment?
  3. Does the VEGF level correlate with tumor histology and behavior?
  4. Is there a relationship between VEGF level and outcome?

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Michigan
      • Marquette, Michigan, United States, 49855
        • Marquette General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients presenting to Marquette General Hospital with a probable or confirmed diagnosis of meningioma or glioma

Description

Inclusion Criteria:

  • any patient presenting with glioma or meningioma

Exclusion Criteria:

  • a different type of brain tumor

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Glioma
patients who are diagnosed with and are being treated for glioma
Procedure: Blood test
an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
meningioma
patients who are diagnosed with and are being treated for meningioma
Procedure: Blood test
an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Determine if VEGF levels correlate with tumor progression or recurrence
Time Frame: every one to three months
every one to three months

Secondary Outcome Measures

Outcome Measure
Time Frame
Determine if the VEGF level is an indicator of the response to treatment.
Time Frame: Every one to three months
Every one to three months
Determine if the VEGF level correlates with tumor histology and behavior.
Time Frame: Every one to three months
Every one to three months
Determine if there is a relationship between VEGF level and outcome.
Time Frame: Every one to three months
Every one to three months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Marquette General Health System

Collaborators

Upper Michigan Brain Tumor Center

Investigators

  • Principal Investigator: Richard A Rovin, MD, FACS, Upper Michigan Brain Tumor Center
  • Principal Investigator: Robert J Winn, PhD, Northern Michigan University
  • Principal Investigator: Suresh Nukala, MD, Marquette General Health Systems

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2009

Primary Completion (ANTICIPATED)

September 1, 2011

Study Completion (ANTICIPATED)

January 1, 2012

Study Registration Dates

First Submitted

September 25, 2009

First Submitted That Met QC Criteria

September 25, 2009

First Posted (ESTIMATE)

September 28, 2009

Study Record Updates

Last Update Posted (ESTIMATE)

April 24, 2012

Last Update Submitted That Met QC Criteria

April 20, 2012

Last Verified

April 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MGH-VEGF-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe